• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Silence Therapeutics Plc - American Depository Share (NQ:SLN)

    19.61 +0.03 (+0.15%)
    Delayed Quote Updated: 4:00 PM EDT, Oct 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 13,962,918
    Open 19.58
    Bid (Size) 19.58 (200)
    Ask (Size) 19.63 (100)
    Prev. Close 19.58
    Today's Range 19.57 - 19.65
    52wk Range 4.190 - 19.65
    Shares Outstanding 107,808,471
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Nasdaq Session Unusual Volume Movers: Gainers and Decliners ↗
    Via Chartmill
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq – SLN), Option Care Health, Inc. (Nasdaq – OPCH), RXO Inc. (NYSE – RXO), Sangoma Technologies Corporation (Nasdaq – SANG)
    From Brodsky & Smith LLC
    Via GlobeNewswire

    Performance

    52-Week Range 0.2% below 52-week high
    19.61
    4.1952W Low 19.6552W High
    1 Week 0.2% below 1-week high
    8.661W Low 19.651W High

    Silence Therapeutics Plc - American Depository Share (SLN) traded between $4.19 and $19.65 over the past 52 weeks and last traded at $19.61, 0.2% below its 52-week high. Over the past week it ranged between $8.66 and $19.65.

    Past 12 Months
    +118.4%
    +60.1%
    +80.7%
    +153.7%
    +218.9%
    +172.7%
    1W +$10.63
    1M +$7.36
    3M +$8.76
    6M +$11.88
    YTD +$13.46
    1Y +$12.42

    SLN was +172.7% over the past year, +153.7% over six months, +218.9% year to date, +118.4% in the last week.

    12 Months vs Market
    SLN
    +172.7%
    DIA
    +12.3%
    SPY
    +14.6%
    QQQ
    +17.3%
    IWM
    +11.1%

    Over the past 12 months SLN returned +172.7% versus DIA (Dow) +12.3%, SPY (S&P 500) +14.6%, QQQ (Nasdaq 100) +17.3% and IWM (Russell 2000) +11.1%.

    Volume & Liquidity 5.55× 3-mo avg
    Today 13,962,918 3-mo avg 2.5M
    1W
    18.2M
    1M
    4.9M
    3M
    2.5M
    6M
    1.5M
    YTD
    1.1M
    1Y
    892.4K

    SLN most recently traded 13,962,918 shares against a 3-month average daily volume of 2.5M.

    More News

    Read More
    Today's Top US Stock Movers: Small-Cap Gainers and Losers ↗
    Via Chartmill
    Today's Top Market Movers: Silence Therapeutics Jumps 126%, CL Workshop Slides 43% ↗
    Via Chartmill
    Gap-Up and Gap-Down Movers for Oct. 19, 2026 ↗
    Via Chartmill
    News headline image
    SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics to Participate in Three September Investor Conferences
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial ↗
    Via MarketBeat
    News headline image
    Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
    From Silence Therapeutics plc
    Via Business Wire
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics to Participate in Jefferies Global Healthcare Conference
    From Silence Therapeutics plc
    Via Business Wire
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
    From Silence Therapeutics plc
    Via Business Wire
    News headline image
    Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
    From Silence Therapeutics plc
    Via Business Wire
    Keep an eye on the top gainers and losers in Wednesday's session. ↗
    Via Chartmill
    Traders are paying attention to the gapping stocks in Wednesday's session. ↗
    Via Chartmill
    Top movers in Thursday's session ↗
    Via Chartmill

    Frequently Asked Questions

    Is Silence Therapeutics Plc - American Depository Share publicly traded?
    Yes, Silence Therapeutics Plc - American Depository Share is publicly traded.
    What exchange does Silence Therapeutics Plc - American Depository Share trade on?
    Silence Therapeutics Plc - American Depository Share trades on the Nasdaq Stock Market
    What is the ticker symbol for Silence Therapeutics Plc - American Depository Share?
    The ticker symbol for Silence Therapeutics Plc - American Depository Share is SLN on the Nasdaq Stock Market
    What is the current price of Silence Therapeutics Plc - American Depository Share?
    The current price of Silence Therapeutics Plc - American Depository Share is 19.61
    When was Silence Therapeutics Plc - American Depository Share last traded?
    The last trade of Silence Therapeutics Plc - American Depository Share was at 10/20/26 04:00 PM ET
    What is the market capitalization of Silence Therapeutics Plc - American Depository Share?
    The market capitalization of Silence Therapeutics Plc - American Depository Share is 2.11B
    How many shares of Silence Therapeutics Plc - American Depository Share are outstanding?
    Silence Therapeutics Plc - American Depository Share has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.